Marnix Van Loock is Scientific Director within the Infectious Diseases & Vaccines Discovery team of Janssen Pharmaceutica NV (Johnson & Johnson), located in Beerse. He currently combines the role of dengue early compound development team leader (eCDTL) within Global Public Health R&D, with a leading role in flavivirus drug discovery within IDV Discovery. Marnix has over 15 years of experience in pharmaceutical research and development and is a member of Organovir’s Advisory Board.
About Johnson & Johnson
At Johnson & Johnson, we believe good health is the foundation of vibrant lives, thriving communities and forward progress. That’s why for more than 130 years, we have aimed to keep people well at every age and every stage of life. Today, as the world’s largest and most broadly based healthcare company, we are committed to using our reach and size for good. We strive to improve access and affordability, create healthier communities, and put a healthy mind, body and environment within reach of everyone, everywhere. Every day, our more than 130,000 employees across the world are blending heart, science and ingenuity to profoundly change the trajectory of health for humanity.